Stock Events

Stock Events

Corcept Therapeutics 

$45.47
112
-$0.69-1.49% Thursday 15:30

Statistics

Day High
46.8
Day Low
44.26
52W High
90.71
52W Low
32.12
Volume
600
Avg. Volume
-
Mkt Cap
4.84B
P/E Ratio
0.51
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.11
0.07
0.25
0.43
Expected EPS
-0.10869
Actual EPS
N/A

Financials

13.09%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.52BRevenue
199.3MNet Income

Analyst Ratings

88.33Average Price Target
The highest estimate is 110.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0I3Q.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap368.57B
AbbVie competes in the pharmaceuticals space, focusing on therapies that could directly compete with Corcept's treatments in endocrine and metabolic diseases.
Pfizer
PFE
Mkt Cap156.77B
Pfizer operates in various therapeutic areas, including endocrinology, potentially competing with Corcept's hormone-related therapies.
Merck
MRK
Mkt Cap294.39B
Merck is involved in developing medications for a wide range of conditions, including those that could compete with Corcept's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol Myers Squibb develops drugs in multiple therapeutic areas, including those that could compete with Corcept's products in hormonal and metabolic diseases.
Novartis
NVS
Mkt Cap293.34B
Novartis offers a broad portfolio of drugs, including treatments for endocrine disorders, directly competing with Corcept's market.
AMGEN
AMGN
Mkt Cap191.53B
Amgen focuses on innovative therapeutics, including endocrine and metabolic disorders, which could compete with Corcept's therapies.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, known for its work in antiviral drugs, also explores treatments in other areas that could compete with Corcept's focus on metabolic and endocrine disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals focuses on developing drugs for a wide range of diseases, including potential competition in the endocrine and metabolic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, potentially including those that compete with Corcept's niche in hormonal therapies.

About

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Joseph K. Belanoff M.D.
Employees
730
Country
United States
ISIN
US2183521028

Listings

MI
IT
1CORT.MI
STU
DE
HTD.STU
MU
DE
HTD.MU
BOATS
BOATS
CORT.BOATS

0 Comments

Share your thoughts

FAQ

What is Corcept Therapeutics stock price today?▼
The current price of 0I3Q.LSE is $45.47 USD — it has decreased by -1.49% in the past 24 hours. Watch Corcept Therapeutics stock price performance more closely on the chart.
What is Corcept Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corcept Therapeutics stocks are traded under the ticker 0I3Q.LSE.
Is Corcept Therapeutics stock price growing?▼
0I3Q.LSE stock has fallen by -1.16% compared to the previous week, the month change is a +33.79% rise, over the last year Corcept Therapeutics has showed a -39.45% decrease.
What is Corcept Therapeutics market cap?▼
Today Corcept Therapeutics has the market capitalization of 4.84B
When is the next Corcept Therapeutics earnings date?▼
Corcept Therapeutics is going to release the next earnings report on May 06, 2026.
What were Corcept Therapeutics earnings last quarter?▼
0I3Q.LSE earnings for the last quarter are 0.2 USD per share, whereas the estimation was 0.33 USD resulting in a -39.3% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corcept Therapeutics revenue for the last year?▼
Corcept Therapeutics revenue for the last year amounts to 1.52B USD.
What is Corcept Therapeutics net income for the last year?▼
0I3Q.LSE net income for the last year is 199.3M USD.
How many employees does Corcept Therapeutics have?▼
As of April 24, 2026, the company has 730 employees.
In which sector is Corcept Therapeutics located?▼
Corcept Therapeutics operates in the Other sector.
When did Corcept Therapeutics complete a stock split?▼
Corcept Therapeutics has not had any recent stock splits.
Where is Corcept Therapeutics headquartered?▼
Corcept Therapeutics is headquartered in Redwood City, United States.